https://www.diwou.com/2023/05/08/innovent-updates-the-results-from-the-orient-31-study-of-sintilimab-plus-chemotherapy-with-or-without-bevacizumab-in-patients-with-egfr-tki-failed-egfr-mutated-non-squamous-non-small-cell-lung-cancer/
Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or...
May 8, 2023 - ROCKVILLE, Md. and SUZHOU, China, May 8, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that...
innoventupdatesresultsorientstudy
https://www.onclive.com/view/sintilimab-combo-reduces-risk-of-progression-by-54-in-egfr-mutated-nonsquamous-nsclc
Sintilimab Combo Reduces Risk of Progression by 54% in EGFR-Mutated Nonsquamous NSCLC | OncLive
Oct 6, 2026 - The addition of sintilimab to a bevacizumab biosimilar and pemetrexed/cisplatin resulted in a statistically significant and clinically meaningful improvement...
sintilimabcomboreducesriskprogression
https://www.hodgkinlymphom.de/pd-1-inhibitor-sintilimab-aus-china/
PD-1-Inhibitor Sintilimab aus China - Hodgkin Lymphom Forum
Feb 15, 2019 - Nivolumab und Pembrolizumab könnten demnächst Konkurrenz vom chinesischen Markt bekommen. Chinesische Forscher haben mit Sintilimab einen neuen PD-1-Inhibitor...
hodgkin lymphominhibitorsintilimabauschina